Methylprednisolone Sodium Succinate 125mg Vial from Canada
Injectable lyophilized powder vial of 125mg methylprednisolone sodium succinate for IV/IM administration in acute conditions like anaphylaxis. HTS 3004.32.00.40 applies as it's a measured dose product containing methylprednisolone salts for therapeutic use.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals Annex IV: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Include sterility testing certificates and endotoxin reports; FDA requires them for injectables
• Declare as 'sterile pharmaceutical' to trigger proper biologics review pathway